PT - JOURNAL ARTICLE AU - Elizabeth S. Partan AU - Francine Blei AU - Sarah L. Chamlin AU - Olivia M. T. Davies AU - Beth A. Drolet AU - Ilona J. Frieden AU - Ioannis Karakikes AU - Chien-Wei Lin AU - Anthony J. Mancini AU - Denise Metry AU - Anthony Oro AU - Nicole S. Stefanko AU - Laksshman Sundaram AU - Monika Tutaj AU - Alexander E. Urban AU - Kevin C. Wang AU - Xiaowei Zhu AU - Nara Sobreira AU - Dawn H. Siegel TI - Analysis of Whole Genome Sequencing in a Cohort of Individuals with PHACE Syndrome Suggests Dysregulation of RAS/PI3K Signaling AID - 10.1101/2021.08.05.21261553 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.05.21261553 4099 - http://medrxiv.org/content/early/2021/08/09/2021.08.05.21261553.short 4100 - http://medrxiv.org/content/early/2021/08/09/2021.08.05.21261553.full AB - The acronym PHACE stands for the co-occurrence of posterior brain fossa malformations, hemangiomas, arterial anomalies, cardiac defects, and eye abnormalities. The majority of patients have a segmental hemangioma and at least one developmental structural anomaly. The etiology and pathogenesis are unknown. Here we discuss the candidate causative genes identified in a de novo analysis of whole genome sequencing of germline samples from 98 unrelated trios in which the probands had PHACE, all sequenced as part of the Gabriella Miller Kids First Pediatric Research Program. A g:Profiler pathway analysis of the genes with rare, de novo variants suggested dysregulation of the RAS/MAPK and PI3K/AKT pathways that regulate cell growth, migration, and angiogenesis. These findings, along with the developmental anomalies and the vascular birthmark, support including PHACE within the RASopathy family of syndromes.Competing Interest StatementFrancine Blei has received honoraria and non-drug related educational grants from Pierre Fabre. Sarah Chamlin is a speaker for Sanofi Genzyme and Regeneron Pharmaceuticals. Beth Drolet is a consultant and on the clinical advisory board for Venthera. Ilona Frieden serves on the Data Safety monitoring boards for Pfizer, is a consultant and advisory board member for Novartis, and is a consultant for Venthera. Dawn Siegel has received royalties from UpToDate, is a consultant for Arqule/Merck, and received a SID SUN mid-career investigator award.Funding StatementThe results analyzed and shown here are based in part upon data generated by Gabriella Miller Kids First Pediatric Research Program (Kids First) projects phs001785.v1.p1. Kids First was supported by the Common Fund of the Office of the Director of the National Institutes of Health (commonfund.nih.gov/KidsFirst). The Hudson-Alpha Institute for Biotechnology was awarded a U24HD090744-01 to sequence structural birth defect cohort samples submitted by investigators through the Kids First program (1X01HL140519-01). This study was supported by the NICHD, NHLBI, and NIAMS under award numbers 1X01HL14519, R03HD098526, and R01AR064258, respectively. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional support was received from a SID SUN grant, PHACE Foundation Canada, and the Children's Research Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Medical College of Wisconsin IRB # PRO00034867All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDatasets related to this article are accessible through the Kids First Data Resource Portal (kidsfirstdrc.org) and/or dbGaP (ncbi.nlm.nih.gov/gap) accession phs001785.v1.p1.SNVsingle nucleotide variantCNVcopy number variantECMextracellular matrix